been a major complication often limiting its usefulness. This study was undertaken to
evaluate the effect of aminocaproic acid (AMICAR), an inhibitor of fibrinolysis, on all
hemorrhagic complications of ECMO including intracranial hemorrhage (ICH). In 1990, 49
neonates and 5 older children received ECMO therapy. None of these patients received
AMICAR. In 1991, 51 neonates and 5 older children received ECMO. Forty-two of these …